E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)

Donesta Bioscience

Status and phase: Completed; Phase 2

Conditions: Hot Flushes

Treatments: Drug: Estetrol; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02834312

2015-004018-44 (EudraCT Number)

MIT-Do0001-C201

Details and patient eligibility

About

This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.

Full description

Oestrogen therapy is the most consistently effective treatment used in the US and Europe for menopausal VMS. Following the safety issues reported in the primary Women's Health Initiative publications and with continued subject requests for treatment, a challenge to clinicians has been to identify the lowest effective dose of oestrogen for alleviating menopausal symptoms. In addition, it is a challenge to develop a safer oestrogen than those currently used.

For this purpose, the minimum effective dose (MED) of E4 has to be defined for the treatment of menopausal symptoms. The present study is intended to evaluate changes in frequency and in severity of moderate to severe VMS in order to define the MED.

Subjects will be randomly allocated to either treatment group (2.5 mg E4, 5 mg E4, 10 mg E4, 15 mg E4, or placebo) in a 1:1:1:1:1 ratio. All treatments (E4 or Placebo) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.

Enrollment: 260 patients

Sex: Female

Ages: 40 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Women presenting at least 7 moderate to severe hot flushes/day or at least 50 moderate to severe hot flushes/week in the week preceding randomization.
• Body Mass Index (BMI) between 18.0 and 35.0 kg/m², inclusive.
• Post-menopausal status.
• Intact uterus.
• Negative pregnancy test.
• Good physical and mental health.
• Subject has provided signed and dated written informed consent before admission to the study.
• Subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.

Exclusion criteria

• Uterine disease or any medical conditions associated with an increase in endometrial thickness.
• Any history of malignancy with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within the prior one year) carcinoma of the skin. Any clinically significant findings at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer.
• Abnormal cervical Pap smear.
• Systolic blood pressure (BP) outside the range 90 to 140 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 40 to 100 bpm.
• Any clinically significant abnormality identified on the screening 12-lead ECG.
• History of venous or arterial thromboembolic disease, history of known coagulopathy or abnormal coagulation factors.
• Diabetes mellitus with poor glycaemic control.
• Dyslipoproteinaemia at screening.
• Smoking >10 cigarettes/day.
• Presence or history of gallbladder disease, unless cholecystectomy has been performed.
• Systemic lupus erythematosus.
• Multiple sclerosis.
• Acute or chronic liver disease.
• Acute or chronic renal impairment.
• Uncontrolled thyroid disorders.
• Use of oestrogen or progestin containing drug(s).
• Use of non-hormonal treatments to reduce hot flushes.
• History or presence of allergy or intolerance to any component of the investigational product.
• History of alcohol or substance abuse or dependence in the 12 months before screening as determined by the Investigator.
• Sponsor, CRO or Investigator's site personnel or their relatives directly affiliated with this study.
• Subjects with known or suspected history of a clinically significant systemic diseases, unstable medical disorders, life-threatening disease or current malignancies that would pose a risk to the subject in the opinion of the Investigator.
• Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to study entry.
• Is judged by the Investigator to be unsuitable for any reason.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

260 participants in 5 patient groups, including a placebo group

2.5 mg estetrol

Experimental group

Treatment:

Drug: Estetrol

5 mg estetrol

Experimental group

Treatment:

Drug: Estetrol

10 mg estetrol

Experimental group

Treatment:

Drug: Estetrol

15 mg estetrol

Experimental group

Treatment:

Drug: Estetrol

placebo

Placebo Comparator group

Treatment:

Drug: Placebo